All Videos

The author of a new study on JAK inhibitors discusses his surprising findings on the safety profiles of these new medications for dermatologic conditions.

Mark G. Lebwohl, MD, and Alice B. Gottlieb, MD, PhD, discuss gaps in care for the treatment of plaque psoriasis.

Expert dermatologists discuss the methods of a study of US health records of patients with generalized pustular psoriasis.

Aaron S. Farberg, MD, and Jeffrey Crowley, MD, provide an overview of generalized pustular psoriasis, identifying flares, the burden on patients, and available treatment options.

Robert Kirsner, MD, PhD, discusses how to heal difficult wounds at the 2022 SDPA Fall Conference.

At the 2022 SDPA Conference, Cynthia Trickett, PA-C, MPAS talks about her 2 sessions; psoriasis primer and kodachromes.

Renata Block, MMS, PA-C., explains the importance of The Society of Dermatology Physician Assistants (SDPA) 2022 Conference.

Shanna Miranti, MPAS, PA-C, shares highlights from her shared session at the 2022 SDPA Conference.

Shanna Miranti, MPAS, PA-C, shares highlights from her first session at the 2022 SDPA Conference in Miami, Florida.

In this week’s Pointers with Dr Portela, the 208SkinDoc reacts to questionable online beauty hacks.

Experts share clinical insights boxed warning for the JAK inhibitor drug class.

Dr Mark Lebwohl provides insight into the educational needs of both patients and providers surround the utilization of spesolimab and its importance in the management of patients with generalized pustular psoriasis.

Mark G. Lebwohl, MD, comments on the clinical implications of the recent approval of spesolimab for the treatment of generalized pustular psoriasis.

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, explore the burden of itch in atopic dermatitis, and why JAK inhibitors may be able to provide relief.

An expert in dermatology presents the case of a 64-year-old female with a long history of plaque psoriasis, focusing on her disease severity and age-related management considerations.

Expert dermatologists discuss the risk of candidiasis with IL-17 inhibitors when managing plaque psoriasis and how to manage candidiasis.

Drs Mark G. Lebwohl and Alice B. Gottlieb discuss the novel mechanism of bimekizumab and how it can change the treatment landscape for plaque psoriasis.

In this week’s Pointers with Dr Portela, the 208SkinDoc reviews RoC's Fill + Treat Serum.

November kicks off National Healthy Skin Month, presenting an opportunity to learn new habits for healthier skin.

Valisure, an independent laboratory, recently sent a Citizen's Petition to the FDA regarding high levels of benzene found in dry shampoo products.

Goals of generalized pustular psoriasis treatment are reviewed by Dr Mark Lebwohl, where he comments on the need to consider patient disease severity and comorbidities.

Dr Mark Lebwohl comments on the treatment and management considerations for a patient suffering from severe generalized pustular psoriasis, highlighting the inefficiency of systemic steroids in the management of this condition.

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, talk about the use of oral systemic agents and what they’ve learned about the patient experience from the use of these agents.

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, examine the clinical context for the approval of topical ruxolitinib and its role in the treatment armamentarium.

Mark G. Lebwohl, MD, introduces the case of a 28-year-old female nurse with a long history of psoriasis, commenting on her past medical history and initial presentation.

Mark G. Lebwohl, MD, and Alice B. Gottlieb, MD, PhD, discuss the durability of IL-17 inhibitors in managing plaque psoriasis.

Expert dermatologists discuss how to select treatment for plaque psoriasis while taking comorbidities into consideration.

In this week’s Pointers with Dr Portela, the 208SkinDoc discusses a rare form of skin cancer, Merkel cell carcinoma.

Thought leaders discuss why JAK inhibitors are well suited for the management of itch and inflammation in the treatment of moderate to severe atopic dermatitis.

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, review the recent trajectory of the atopic dermatitis therapeutic spectrum, notably how several newer approvals have changed how clinicians approach treatment.